Cardiovascular disease has become increasingly prevalent in the HIV population. Antiretroviral therapy and HIV itself independently increase the risk of dyslipidemia. While statins are currently the predominant therapy to treat dyslipidemia in HIV patients, drug-drug interactions and adverse drug events can limit their use. Proprotein convertase subtilisin/kexin type 9 inhibitors have shown promising results in preliminary trials by significantly reducing low density lipoprotein and other atherogenic lipid levels. They should be considered as an early intervention alongside statins in HIV patients with dyslipidemia.

中文翻译：

---

PCSK9 抑制剂 - HIV 血脂异常的新希望。

心血管疾病在艾滋病毒人群中变得越来越普遍。抗逆转录病毒治疗和艾滋病毒本身会独立增加血脂异常的风险。虽然他汀类药物目前是治疗 HIV 患者血脂异常的主要疗法，但药物相互作用和药物不良事件可能限制其使用。前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型抑制剂在初步试验中显示出可喜的结果，可显着降低低密度脂蛋白和其他致动脉粥样硬化的脂质水平。它们应被视为与他汀类药物一起对患有血脂异常的艾滋病毒患者进行早期干预。